THRX
NASDAQTheseus Pharmaceuticals Inc.
Latest news
25 items- SECSEC Form 15-12G filed by Theseus Pharmaceuticals Inc.15-12G - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
- 13D/GSEC Form SC 13D/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- SECSEC Form EFFECT filed by Theseus Pharmaceuticals Inc.EFFECT - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
- INSIDERSEC Form 4 filed by Yi Kathy4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- INSIDERSEC Form 4 filed by Stein Steven H4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- INSIDERHayden Donald J Jr closing all direct ownership in the company (SEC Form 4)4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- INSIDERDukes Iain D. closing all direct ownership in the company (SEC Form 4)4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- INSIDERSEC Form 4 filed by Gordon Carl L4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- INSIDERDahms Bradford D. closing all direct ownership in the company (SEC Form 4)4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
- SECSEC Form S-8 POS filed by Theseus Pharmaceuticals Inc.S-8 POS - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
- SECSEC Form S-8 POS filed by Theseus Pharmaceuticals Inc.S-8 POS - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
- SECSEC Form POS AM filed by Theseus Pharmaceuticals Inc.POS AM - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
- SECTheseus Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
- SECSEC Form SC 14D9/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 14D9/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- SECSEC Form 25-NSE filed by Theseus Pharmaceuticals Inc.25-NSE - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- PRTheseus Pharmaceuticals Announces Closing of Tender Offer-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass., Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra Biosciences, LLC ("Concentra") through its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4
- 13D/GSEC Form SC 13G/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 13G/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- SECSEC Form SC 14D9/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 14D9/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- SECSEC Form SC 14D9/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 14D9/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- NEWSPursuant To Merger Agreement Terms, Concentra Merger Sub II And Theseus Determine Additional Price Per Share Max Of $0.15/Share; Cash Amount Paid In Offer Is $4.05/ShareAs previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement") with Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus") whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of up to $0.15 per share (the "Additional Price Per Share" and together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR") r
- PRConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsAs previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement") with Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus") whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of up to $0.15 per share (the "Additional Price Per Share" and together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR")
- 13D/GSEC Form SC 13D/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- SECSEC Form SC 14D9 filed by Theseus Pharmaceuticals Inc.SC 14D9 - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
- 13D/GSEC Form SC 13D/A filed by Theseus Pharmaceuticals Inc. (Amendment)SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
THRX FAQ
7 questionsWhat does Theseus Pharmaceuticals Inc. do?
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or...Where does THRX stock trade?
Theseus Pharmaceuticals Inc. (THRX) is listed on NASDAQ.What sector and industry is THRX in?
Theseus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Theseus Pharmaceuticals Inc. go public?
Theseus Pharmaceuticals Inc. (THRX) completed its IPO in 2004.What are analysts saying about THRX?
Theseus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Hold on 2023-07-14. Recent price targets range from $2200.00 to $2800.00.What companies are similar to THRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare THRX side-by-side with any of them on Quantisnow.How can I track THRX on Quantisnow?
Quantisnow aggregates Theseus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow THRX to receive live email and push alerts on every new disclosure.